Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07332143 · ClinicalTrials.gov registry record · Phase 2
Psilocybin-Assisted Therapy
A Phase 2 study, sponsored by Emory University.
- Not yet
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
NCT07332143: Clinical Trial Phase 2 study, sponsored by Emory University.
NCT07332143 is a Phase 2 study that has not yet begun recruiting, run by Emory University. The registered enrollment target is 150 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (13% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07332143, a Phase 2 study, has not yet begun recruiting, sponsored by Emory University.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
Study Summary
This pilot study will examine the safety, tolerability, acceptability, and efficacy of combination psilocybin + psychotherapy to decrease PTSD symptoms. Participants will be randomized into two different treatment groups, allowing the investigators to directly compare PE augmented with psilocybin and psilocybin-assisted psychotherapy.
Primary Outcome
PTSD symptoms will be evaluated using the Revised Clinician-Administered PTSD Scale for DSM-5, that refers to 20 core symptoms as CAPS-5, each rated on a 0-4 severity scale (0 = absent to 4 = extremely severe), combining frequency and intensity. Total possible score range is 0 to 80 with higher scores correlating with worse outcome.
Interventions
- BEHAVIORAL Supportive Therapy
- BEHAVIORAL Prolonged Exposure Therapy
- DRUG psilocybin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2026-06 |
| Est. Completion | 2027-03 |
| Phase | Phase 2 |
What is known before NCT07332143 opens enrollment
NCT07332143 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (13% higher).
The record links to 0 conditions, and to 3 interventions - of which Supportive Therapy is the first listed.
NCT07332143 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07332143 about?
NCT07332143 is a clinical study titled "Psilocybin-Assisted Therapy". This pilot study will examine the safety, tolerability, acceptability, and efficacy of combination psilocybin + psychotherapy to decrease PTSD symptoms. Participants will be randomized into two different treatment groups, allowing the investigators to directly compare PE augmented with psilocybin an...
What is the current status of trial NCT07332143?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2026-06. Estimated completion is 2027-03.
What interventions are being tested in trial NCT07332143?
The interventions under investigation include: Supportive Therapy (BEHAVIORAL), Prolonged Exposure Therapy (BEHAVIORAL), psilocybin (DRUG).
Who is sponsoring clinical trial NCT07332143?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07332143's enrollment target sits among peer trials
150 455th of 2000 higher than 1,510 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia